Protocol Title: Investigation of Rheumatic AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies (INVICTUS)

Sponsor / Coordinating Site– All India Institute of Medical Sciences (AIIMS)

Principal investigator – Dr.  G. Karthikeyan

Funding Agency – Population Health Research Institute (PHRI)

In patients with RVHD and who are in AF and have other stroke risk factors, rivaroxaban is non-inferior to vitamin K antagonists (VKAs) for prevention of stroke or systemic embolism.

The study is a comprehensive evaluation of Rheumatic Valvular Heart Disease (RVHD), Atrial Fibrillation or flutter (AF) and stroke to establish the efficacy and safety of rivaroxaban in a broad cross section of patients at substantial risk of stroke and death. Currently this program is being carried out in 24 countries at 163 active clinical centres. In India, CDSA has extended pre-study activities support for project management, data monitoring, IP management and safety reporting in 08 tertiary care hospitals. CDSA has implemented Risk- Based Monitoring (RBM).

Study specific webpage link:

CTRI Registration link: INVICTUS STUDY

The Team

  • Ms. Shubhra Bansal
  • Mr. Tarun Puri
  • Ms. Jinisha Shukla